Market Cap 2.13B
Revenue (ttm) 0.00
Net Income (ttm) -154.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 946,700
Avg Vol 1,565,128
Day's Range N/A - N/A
Shares Out 82.50M
Stochastic %K 88%
Beta 0.57
Analysts Strong Sell
Price Target $49.00

Company Profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name t...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Road, Suite F200, Radnor, United States
CH_Expat
CH_Expat Jun. 24 at 7:00 PM
$MLYS @CDMO You see what I did? Bought 90% higher than my initial post.
0 · Reply
CH_Expat
CH_Expat Jun. 24 at 6:31 PM
$MLYS Added 1000. Novartis or Novo will buy it. L will do 2b peak sales.
1 · Reply
CH_Expat
CH_Expat Jun. 24 at 3:37 PM
$MLYS One of the last undervalued quality bios.
0 · Reply
Quantumup
Quantumup Jun. 22 at 11:43 AM
Guggenheim⬆️ $TENX-$40,⬆️PoS, reiterated Buy and said it sees a pot'l >200% move. $TECX MRK $MLYS AZN CYTK EWTX TNYA Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2069023120770375960?s=20
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 19 at 7:55 PM
$SRRK trades at the highest multiple of analyst consensus revenue estimates of the 6 bios noted on the attachment with active PDUFA dates. This is not investment advice. We're only sharing an observation around SRRK's high multiple versus the 5 peers. Can anyone pushback? $MLYS just closed an equity financing not 3 weeks ago at $26.50 per share. $VRDN trades at the lowest multiple. We do not follow VRDN in any detail but we understand VRDN owes DRI Healthcare a 7.5% royalty on all Elogrobart sales. Even though we read Amgen's Tepezza is better in TED, investors closed a $350MM convertible debt offering after the data was published so WTF do we know. $VERA closed a financing last December at $42.50/share last December. We read analysts project Atacicept peak sales of $1.2 to $2.2B. VERA appears to be the best value of the 6 just based on multiples. $PRAX 52-week high was $366/share before reporting its Vormatrigine data earlier this month. Again we'd genuinely like to understand SRRK
2 · Reply
ValueBioTracker
ValueBioTracker Jun. 19 at 11:20 AM
$MLYS Let the uptrend begin. Higher highs, higher lows
0 · Reply
aak12345
aak12345 Jun. 18 at 8:07 PM
$MLYS I rode this from 13 to 29 last year. Now back again for approval and (hopefully) buyout.
0 · Reply
Diiiii
Diiiii Jun. 18 at 3:36 AM
$MLYS The Management Teamas a Strategic Asset (Mineralys Therapeutics) Why the four executives steering $MLYS may be as significant to the acquisition thesis as lorundrostat itself. https://claude.ai/public/artifacts/cfde9704-0fea-439e-9ed8-32277aaeb548
0 · Reply
Jakeipedia
Jakeipedia Jun. 17 at 6:00 PM
$MLYS as I’m sure Patrick Henry would agree. Give me a buy out or give me death
1 · Reply
ValueBioTracker
ValueBioTracker Jun. 17 at 2:47 PM
$MLYS all one needs here is patience. Nothing is more obvious than this one reaching +$40 by the PDUFA date with high chance of BO around $60
1 · Reply
Latest News on MLYS
Mineralys Therapeutics falls -17.1%

2026-06-03T16:06:46.000Z - 22 days ago

Mineralys Therapeutics falls -17.1%


Mineralys Therapeutics falls -12.7%

2026-06-03T15:57:06.000Z - 22 days ago

Mineralys Therapeutics falls -12.7%


Mineralys Therapeutics presents new data for lorundrostat

2026-05-31T21:05:04.000Z - 25 days ago

Mineralys Therapeutics presents new data for lorundrostat


Mineralys' pill cuts blood pressure in kidney disease patients

May 30, 2026, 11:20 AM EDT - 26 days ago

Mineralys' pill cuts blood pressure in kidney disease patients


Mineralys Therapeutics Transcript: AGM 2026

May 21, 2026, 3:30 PM EDT - 5 weeks ago

Mineralys Therapeutics Transcript: AGM 2026


Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)

2026-05-07T00:50:30.000Z - 7 weeks ago

Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)


Mineralys Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2026


Mineralys Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Mineralys Therapeutics Earnings release: Q1 2026


Mineralys Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 7 weeks ago

Mineralys Therapeutics Quarterly report: Q1 2026


Mineralys Therapeutics Slides: Corporate presentation

May 6, 2026, 4:00 PM EDT - 7 weeks ago

Mineralys Therapeutics Slides: Corporate presentation


Mineralys Therapeutics initiated with a Buy at TD Cowen

2026-04-27T09:40:39.000Z - 2 months ago

Mineralys Therapeutics initiated with a Buy at TD Cowen


Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Proxy statement: Proxy filing


Mineralys Therapeutics Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Mineralys Therapeutics Proxy statement: Proxy filing


Mineralys Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Mineralys Therapeutics Slides: Corporate presentation


Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)

2026-03-12T20:36:58.000Z - 3 months ago

Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)


Mineralys Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2025


Mineralys Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Annual report: Q4 2025


Mineralys Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Mineralys Therapeutics Earnings release: Q4 2025


Mineralys Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2025


Mineralys Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Mineralys Therapeutics Quarterly report: Q3 2025


Mineralys Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Mineralys Therapeutics Earnings release: Q3 2025


Mineralys Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Mineralys Therapeutics Slides: Corporate Presentation


Mineralys Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 7:00 AM EDT - 9 months ago

Mineralys Therapeutics Slides: Corporate Presentation


Mineralys Therapeutics Slides: Corporate Presentation

Sep 4, 2025, 2:00 AM EDT - 10 months ago

Mineralys Therapeutics Slides: Corporate Presentation


Mineralys Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Mineralys Therapeutics Earnings Call Transcript: Q2 2025


Mineralys Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Mineralys Therapeutics Quarterly report: Q2 2025


Mineralys Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Mineralys Therapeutics Earnings release: Q2 2025


Mineralys Therapeutics Transcript: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result


Mineralys Therapeutics Press release: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result


Mineralys Therapeutics Slides: Study Result

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result


Mineralys Therapeutics Slides: FY 2025

May 25, 2025, 11:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: FY 2025


Mineralys Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q1 2025


Mineralys Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Quarterly report: Q1 2025


Mineralys Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Mineralys Therapeutics Earnings release: Q1 2025


Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing


Mineralys Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Proxy statement: Proxy Filing


Mineralys Therapeutics Transcript: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: KOL Event


Mineralys Therapeutics Slides: KOL Event

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: KOL Event


Mineralys Therapeutics Transcript: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Transcript: Study Result


Mineralys Therapeutics Press release: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Press release: Study Result


Mineralys Therapeutics Slides: Study Result

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Slides: Study Result


Mineralys Therapeutics Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q4 2024


Mineralys Therapeutics Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Annual report: Q4 2024


Mineralys Therapeutics Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q4 2024


Mineralys Therapeutics Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings Call Transcript: Q3 2024


Mineralys Therapeutics Quarterly report: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Quarterly report: Q3 2024


Mineralys Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Mineralys Therapeutics Earnings release: Q3 2024


CH_Expat
CH_Expat Jun. 24 at 7:00 PM
$MLYS @CDMO You see what I did? Bought 90% higher than my initial post.
0 · Reply
CH_Expat
CH_Expat Jun. 24 at 6:31 PM
$MLYS Added 1000. Novartis or Novo will buy it. L will do 2b peak sales.
1 · Reply
CH_Expat
CH_Expat Jun. 24 at 3:37 PM
$MLYS One of the last undervalued quality bios.
0 · Reply
Quantumup
Quantumup Jun. 22 at 11:43 AM
Guggenheim⬆️ $TENX-$40,⬆️PoS, reiterated Buy and said it sees a pot'l >200% move. $TECX MRK $MLYS AZN CYTK EWTX TNYA Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2069023120770375960?s=20
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 19 at 7:55 PM
$SRRK trades at the highest multiple of analyst consensus revenue estimates of the 6 bios noted on the attachment with active PDUFA dates. This is not investment advice. We're only sharing an observation around SRRK's high multiple versus the 5 peers. Can anyone pushback? $MLYS just closed an equity financing not 3 weeks ago at $26.50 per share. $VRDN trades at the lowest multiple. We do not follow VRDN in any detail but we understand VRDN owes DRI Healthcare a 7.5% royalty on all Elogrobart sales. Even though we read Amgen's Tepezza is better in TED, investors closed a $350MM convertible debt offering after the data was published so WTF do we know. $VERA closed a financing last December at $42.50/share last December. We read analysts project Atacicept peak sales of $1.2 to $2.2B. VERA appears to be the best value of the 6 just based on multiples. $PRAX 52-week high was $366/share before reporting its Vormatrigine data earlier this month. Again we'd genuinely like to understand SRRK
2 · Reply
ValueBioTracker
ValueBioTracker Jun. 19 at 11:20 AM
$MLYS Let the uptrend begin. Higher highs, higher lows
0 · Reply
aak12345
aak12345 Jun. 18 at 8:07 PM
$MLYS I rode this from 13 to 29 last year. Now back again for approval and (hopefully) buyout.
0 · Reply
Diiiii
Diiiii Jun. 18 at 3:36 AM
$MLYS The Management Teamas a Strategic Asset (Mineralys Therapeutics) Why the four executives steering $MLYS may be as significant to the acquisition thesis as lorundrostat itself. https://claude.ai/public/artifacts/cfde9704-0fea-439e-9ed8-32277aaeb548
0 · Reply
Jakeipedia
Jakeipedia Jun. 17 at 6:00 PM
$MLYS as I’m sure Patrick Henry would agree. Give me a buy out or give me death
1 · Reply
ValueBioTracker
ValueBioTracker Jun. 17 at 2:47 PM
$MLYS all one needs here is patience. Nothing is more obvious than this one reaching +$40 by the PDUFA date with high chance of BO around $60
1 · Reply
CH_Expat
CH_Expat Jun. 16 at 6:01 PM
$IDYA unchanged, $CRNX I added after strong ENDO-Updates, opened a position at $MLYS, waiting for $TARS to go a bit more southwards. Hard to find value in quality these days. Ready to add CRNX and MLYS on surreal depression.
1 · Reply
Diiiii
Diiiii Jun. 16 at 6:01 AM
$MLYS Mineralys Therapeutics at an Inflection Point: How ENDO 2026 Proteomics Data Redefines the Cardiorenal Platform Thesis and Shapes M&A Dynamics https://claude.ai/public/artifacts/4beb451d-b7b6-483a-8ff0-b7f269d4a05b
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 16 at 1:47 AM
The 5 analysts that provide 10-year $MLYS revenue estimates all project MLYS to generate more product related revenues over the next 10 years than $ACLX , not 1 or 2 analysts but all 5. Of course we have no idea the gross margin profiles for either but if sales are a barometer of potential value then... ACLX was acquired for an enterprise value of $7.3B while MLYS's market cap was $2.1B as of 6/15/26, which does not consider the $650MM MLYS had on their balance sheet at the end of Q1 26 As important, MLYS just closed a meaningful equity raise 2 weeks where accredited investors opted to invest $150MM in MLYS at $26.50. MLYS closed at just under $24.00 today. This is not investment advice but if all 5 analysts believe MLYS' product portfolio will generate meaningfully more sales than ACLX, and ACLX's enterprise value is 4X higher then... $XBI $IBB $NBI
1 · Reply
CH_Expat
CH_Expat Jun. 15 at 1:49 PM
$MLYS Starter 1100 for 23.75 USD.
1 · Reply
AlertsAndNews
AlertsAndNews Jun. 14 at 10:10 PM
$MLYS Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) "Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure "
0 · Reply
CH_Expat
CH_Expat Jun. 13 at 8:40 PM
$MLYS Probably a starter on monday.
1 · Reply
BiodegradableBurger
BiodegradableBurger Jun. 12 at 4:03 PM
$MLYS What a shit show
0 · Reply
Quantumup
Quantumup Jun. 12 at 12:52 PM
Piper Sandler⬆️ $TENX's PT to $50 (was $20), reiterated Overweight and said: With Ph3 LEVEL Coming in 3Q26, Here's Why Now Is The Time to Own & PT Update $TECX MRK AZN CYTK TNYA $MLYS Here's what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2065416152172425604?s=20
0 · Reply
E2Invest
E2Invest Jun. 11 at 12:21 PM
$MLYS PDUFA date of December 22nd 2026. This on is on high watch
0 · Reply
Diiiii
Diiiii Jun. 10 at 4:36 AM
$MLYS Let's dissect the CEO's comments at the GS Healthcare Conference. Regarding the Tanabe royalty buyout, he explicitly stated: "whether alone with a partner or if someday a company wanted to acquire us, in either case it builds value." This might be the first time he so openly dropped the "acquire us" phrase. Here is the logical read-through: • Active Dialogues: Discussions with serious suitors are likely advancing. • The Quiet Auction: MLYS is in a behind-the-scenes bidding phase. This rhetoric broadcasts to mega-pharmas that the window is closing, but still open for final bids. • The Timeline: Due diligence takes time, making an immediate announcement unlikely. However, waiting until the Dec PDUFA forces buyers to pay maximum premium, and waiting until Nov risks a massive pre-approval run-up. IMO: The absolute sweet spot for a buyout announcement is the August–October window. The clock is ticking for buyers.
1 · Reply
ValueBioTracker
ValueBioTracker Jun. 9 at 7:42 PM
$MLYS Awesome interview. They are super confident and it seems that BP discussions are active
1 · Reply
Irish_lass
Irish_lass Jun. 9 at 7:00 PM
$MLYS Let’s 👇🏻
0 · Reply